The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
A message I received this morning from my mate who used to work for Ashfield.
"****. They must have a plan for the clinical development still or they wouldn’t have hired Ashfield Engage. Unless they did that before the results came in, but that would be risky. Might just have to wait and see"
Trouble is, it looks like they did hire Ashfield before results. Have they taken too many risks? Have they thrown caution to wind? **** or bust? However we want to call it..
So I asked a friend of mine who is a medical writer for her opinion based on her experience with trials. I didn't tell her the details, just that SNG are expecting results and would anyone in the company have a heads up.
This is her reply
Hello. They keep it all really confidential unfortunately, even within their own company it will be need to know only. They don’t advertise their results to us either. We have to give a list of less than 5 people who have to sign separate confidentiality agreements until the results are fully published. They will do an announcement for the stakeholders pretty early though. There won’t be many details, just good or bad
After a couple more messages she sent this
So I’ve just looked into it and they’ve actually hired a department from my old company to do their commercial strategy and that is not cheap, in fact it is bloody expensive. It also looks like they should have had a data readout the end of last year so now would be roughly the right time the biostatistics guys would have finished. Based purely on speculation and with no promises, it does sound good. I’d be surprised if you didn’t hear something soon
Not telling anyone anything we didn't already know but its an unbiased opinion from someone in the industry
Elso
No harm in asking..
Would you mind re confirming your definition of "early 22"? As it possibly could be interpreted by different people in different ways. In my mind it is pre-expiry of Q1. Is this your understanding too and would you confirm it please?
Kind regards
Sent
Response to an email I sent on Monday. It's not telling us anything new but it is down in writing that nothing has changed.
Thank you for your interest in Synairgen. As you will know, our SPRINTER (SG018) clinical trial is a double blind, placebo-controlled study designed to evaluate the safety and efficacy of SNG001 in hospitalised COVID-19 patients. The study includes 623 patients, across more than 100 clinical sites, in 17 countries. As is the case with clinical development, once a trial closes, a team of researchers, scientists and statisticians quality check the blinded data and conduct their statistical analysis. In line with our previous disclosure of anticipated timings, the topline data from the analysis of the main study endpoints from the SG018 study is still expected in early 2022 and, once available, will be issued by Synairgen without delay in line with London Stock Exchange rules.
Kind regards,
Kris
Well I don't think the world is too concerned about Russia siding with the supposed 30%. We knew that already. Its how they're going about it that is the issue. Yes. Russia amassing an army on the borders of a sovereign nation that it has already invaded previously is the crisis at this moment in time even.
HSD
Everything you said there I already know.
I meant the Ukrainian government. The democratically elected government that represents the majority. If the majority decide they want annexing then they can vote them out and join Vlad.
So yes, it is that simple